Phase 2 Clinical Study
A study for adults with advanced non-small cell lung cancer.
BEACON NSCLC-04 is evaluating an investigational therapy for people whose cancer has progressed after prior treatment. Research sites are now enrolling participants.
At a glance
Who may qualify
Adults aged 18 and older with advanced non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy.
What is being studied
An investigational combination therapy designed to target resistance pathways that can develop after earlier treatment.
Study duration
Participation includes screening, an active treatment period of up to 12 months, and follow-up visits for up to 6 months after treatment ends.
What participation involves
Participants attend regular clinic visits for study assessments including physical exams, blood tests, imaging scans, and study medication administration. The study team reviews the full visit schedule during the screening process.
All study-related care, medication, and monitoring are provided at no cost. Travel support and reimbursement for time and expenses may be available depending on the research site.
What the study team will discuss with you
- Your medical history and whether the study criteria match your situation
- The treatment plan, including how the investigational therapy is administered
- What to expect at each visit, how long visits typically take, and how often they occur
- Potential risks and benefits of participation
- How to reach the study team between visits if you have questions or concerns
Interested in learning more?
A research coordinator can answer your questions and help you understand whether this study might be right for you.
Learn about the study